34,114 research outputs found
National Aboriginal and Torres Strait Islander cancer framework 2015
No full textOverview
The National Aboriginal and Torres Strait Islander Cancer Framework (the Framework) provides high-level guidance and direction for the many individuals, communities, organisations and governments whose combined efforts are required to address disparities and improve cancer outcomes for Aboriginal and Torres Strait Islander peoples.
This Framework is designed to complement and enhance national, jurisdictional, regional and local efforts to improve Aboriginal and Torres Strait Islander cancer outcomes, including cancer plans and related policies, frameworks and action plans. It sets out priority areas for action, and allows the flexibility for jurisdictions, communities and organisations to address those priorities in ways that suit their local context and local needs.
This Framework encompasses the full continuum of cancer control, including cancer prevention, screening and early detection, diagnosis and treatment, palliative care and survivorship; and the policy, systems, research and infrastructure that surround these service areas
Cancer in Australia: an overview 2014
No full textPresents the latest available information on national population screening programs, cancer incidence, hospitalisations, survival, prevalence and mortality.
Summary
Cancer in Australia: an overview 2014 was prepared by the Australian Institute of Health and Welfare with support from state and territory members of the Australasian Association of Cancer Registries. It provides comprehensive national information and statistics on cancer, including the latest available data and projections, as well as trends over time. Information by Aboriginal and Torres Strait Islander status, state and territory, remoteness area, life stages and socioeconomic disadvantage are also presented.
Cancer is a major cause of illness in Australia
In 2014, it is estimated that 123,920 Australians will be diagnosed with cancer (excluding basal and squamous cell carcinoma of the skin, as these cancers are not notifiable diseases in Australia). More than half (55%) of the cancer cases diagnosed in Australia are expected to be for males. The most commonly reported cancers in 2014 are expected to be prostate cancer, followed by colorectal (bowel) cancer, breast cancer in females, melanoma of the skin, and lung cancer. Between 1982 and 2014, the number of new cancer cases diagnosed more than doubled—from 47,417 to 123,920. This increase can be largely attributed to the rise in the incidence of prostate cancer, colorectal cancer, breast cancer in females and lung cancer. The increase can also be partly explained by the ageing and increasing size of the population, improved diagnoses through population health screening programs, and improvements in technologies and techniques used to identify and diagnose cancer.
Mortality rate due to cancer has fallen
In 2014, it is estimated that nearly 45,780 Australians will die from cancer. Cancer accounted for about 3 in 10 deaths in Australia. For all cancers combined, the age-standardised mortality rate is estimated to decrease by 20%, from 209 per 100,000 in 1982 to 168 per 100,000 in 2014.
Survival improved over time, but not consistent across all cancers
Five-year survival from all cancers combined increased from 46% in 1982–1986 to 67% in 2007–2011. The cancers with the largest survival gains over this time were prostate cancer, kidney cancer and non-Hodgkin lymphoma. People living in Australia who were diagnosed with cancer generally had better survival prospects compared with people living in other countries and regions who were diagnosed with cancer.
Cancer outcomes differ across population groups
Cancer outcomes differ by Aboriginal and Torres Strait Islander status and remoteness area. In 2008–2012, for all cancers combined, Indigenous Australians experienced higher mortality rates than non-Indigenous Australians. In 2005–2009, incidence rates were highest for those living in Inner regional areas of Australia; in 2008–2012, mortality rates were highest for those living in Very remote areas
Cancer in Australia: in brief 2014
No full textPresents key points and trends from the Australian Institute of Health and Welfare’s latest biennial report about cancer in Australia.
Introduction
Cancer is a major cause of illness in Australia and has a substantial social and economic impact on individuals, families and the community. In 2014, it is estimated that 123,920 people will be diagnosed with cancer and 45,780 people will die from cancer. Findings from recent global burden of disease studies show that cancer contributed between 16% and 19% of the total disease burden in Australia.
This booklet provides highlights from the full report Cancer in Australia: an overview 2014. The report is part of a series of national statistical reports on cancer produced by the Australian Institute of Health and Welfare with support from state and territory members of the Australasian Association of Cancer Registries. As a short version, this booklet presents key findings from the main report. Refer to the full report for details about methods and technical information
Prostate cancer in Australia
No full textThis is the first comprehensive national report on prostate cancer in Australia, presenting an overview of the condition and analysis of key summary measures including incidence, mortality and survival.SummaryThe effect of prostate cancer is wide reaching-affecting males diagnosed with the condition, their families and communities. Prostate cancer in Australia is the first comprehensive national report on prostate cancer in Australia. It provides an overview of the condition, its risk factors, diagnosis and management, and key summary measures including incidence, mortality and survival. Comparisons over time and by age, selected population groups and international region are also presented.Prostate cancer is the most commonly diagnosed cancer in AustraliaThere were 21,808 new cases of prostate cancer diagnosed in 2009. The age-standardised incidence of prostate cancer has increased over time, from 79 new cases per 100,000 males in 1982 to 194 per 100,000 in 2009. This increase is expected to continue, reaching 25,000 new cases per year in 2020, due to increases in the number of men presenting for testing, changes in diagnostic practices and the ageing of the population.Mortality rates are decreasingThere were 3,294 deaths from prostate cancer recorded in 2011, making it the fourth leading cause of death among Australian males, behind coronary heart diseases, lung cancer and cerebrovascular diseases. The age-standardised mortality rate has decreased over time, from 34 deaths per 100,000 males in 1982 to 31 deaths per 100,000 in 2011. This decline is expected to continue, to 26 deaths per 100,000 males in 2020.Survival is high and improvingIn 2006-2010, around 9 in 10 (92%) males diagnosed with prostate cancer survived 5 years from diagnosis. This is higher than for all cancers among males (65%), as well as other leading cancers among males, including melanoma of the skin (89%) and lung cancer (13%). Prostate cancer 5-year survival is high and has improved from 59% in 1986 to 90% in 2007.Expenditure on prostate cancer has increased Health-care expenditure on prostate cancer was estimated to be $349 million in 2008-09, an increase of 23% on expenditure in 2004-05. This increase in expenditure on prostate cancer corresponds with the increase in new cases of prostate cancer identified between 2002 and 2008.There are differences between some population groupsAboriginal and Torres Strait Islander males were less likely to be diagnosed with prostate cancer, but similarly likely to die from prostate cancer, compared with non-Indigenous males. Males living in Inner regional areas were more likely to be diagnosed with prostate cancer (186 new cases per 100,000 males) and those living in Remote/Very remote areas were less likely (150 per 100,000), compared with males living in all other regions. The observed differences between these population groups could be due to variations in: rates of presenting for testing, population risk profiles and population age structures
Author Peter FitzSimons speaking at the National Library of Australia, Canberra, 13 November 2012 /
No full textTitle from acquisitions documentation.; Part of the collection: Portraits of author Peter FitzSimons speaking at the National Library of Australia, Canberra, 13 November 2012.; Acquired in digital format; access copy available online.; Mode of access: Online.; Photographed by a staff member of the National Library of Australia
Portrait of author David Foster at the National Library of Australia, Canberra, 8 June 2011 /
No full textTitle from acquisitions documentation.; Part of the collection: Portraits of author David Foster at the National Library of Australia, Canberra, 8 June 2011.; Acquired in digital format; access copy available online.; Mode of access: Online.; Photographed by a staff member of the National Library of Australia
Author, Geraldine Brooks at the National Library of Australia for the 2009 Ray Mathew Lecture, Canberra, 23 October 2009 [picture] /
No full textTitle from acquisitions documentation.; Part of the collection: Portraits of author, Geraldine Brooks during her visit to the National Library of Australia for the 2009 Ray Mathew Lecture, Canberra, 23 October 2009.; Acquired in digital format; access copy available online.; Mode of access: Internet via World Wide Web.; Photographed by a staff member of the National Library of Australia
Author David Foster with academic Jeff Doyle at the National Library of Australia, Canberra, 8 June 2011 /
No full textTitle from acquisitions documentation.; Part of the collection: Portraits of author David Foster at the National Library of Australia, Canberra, 8 June 2011.; Acquired in digital format; access copy available online.; Mode of access: Online.; Photographed by a staff member of the National Library of Australia
Author David Foster and academic Jeff Doyle at the National Library of Australia, Canberra, 8 June 2011 /
No full textTitle from acquisitions documentation.; Part of the collection: Portraits of author David Foster at the National Library of Australia, Canberra, 8 June 2011.; Acquired in digital format; access copy available online.; Mode of access: Online.; Photographed by a staff member of the National Library of Australia
Health system expenditure on cancer and other neoplasms in Australia 2008-09
No full textThis report provides estimates of Australia\u27s health system expenditure on care for those with cancer and on the prevention and treatment of cancer. The report presents cancer expenditure by age group, sex and type of cancer, and it compares health system expenditure on cancer in 2008-09 to 2004-05 and 2000-01 in constant prices (see Glossary). Expenditure estimates included in this report are based on health system expenditure that can be directly attributed to cancer. Not included in this analysis are expenditure on items such as capital goods, including equipment used exclusively for the treatment of individual chronic diseases (such as, linear accelerators for cancer) and expenditure on health administration other than for cancer screening programs (see Chapter 3 for more detail). All references to "total health system expenditure" within this report relate to "total health system expenditure on chronic disease" unless otherwise stated. Not all health system expenditure can be allocated to specific diseases. There are other limitations to the data, and these are explained in Chapter 2.Main findings In 2008-09: Total health system expenditure in Australia on cancer and other neoplasms (excluding national population screening programs) was 65,129 million). Total expenditure (in 2008-09 prices) on cancer has increased from 3,640 million in 2004-05.Cancer ranked sixth in terms of Australia\u27s estimated total health system expenditure on chronic diseases.Cancer expenditure for hospital admitted patient services totalled 420 million (9%), and prescription pharmaceuticals totaled 83 million for people aged 15-24 to a maximum of 332.2 million, comprising 125.2 million for cervical screening, and 184.1 million (BreastScreen Australia and the National Cervical Screening Program). In 2008-09, this increased to $332.2 million (current prices) partly due to the introduction of the National Bowel Cancer Screening Program in 2006
- …
